JP2020531511A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531511A5
JP2020531511A5 JP2020511176A JP2020511176A JP2020531511A5 JP 2020531511 A5 JP2020531511 A5 JP 2020531511A5 JP 2020511176 A JP2020511176 A JP 2020511176A JP 2020511176 A JP2020511176 A JP 2020511176A JP 2020531511 A5 JP2020531511 A5 JP 2020531511A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
patient
eye
micrograms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048025 external-priority patent/WO2019040919A1/en
Publication of JP2020531511A publication Critical patent/JP2020531511A/ja
Publication of JP2020531511A5 publication Critical patent/JP2020531511A5/ja
Pending legal-status Critical Current

Links

JP2020511176A 2017-08-24 2018-08-24 眼球用医薬組成物 Pending JP2020531511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549872P 2017-08-24 2017-08-24
US62/549,872 2017-08-24
PCT/US2018/048025 WO2019040919A1 (en) 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS

Publications (2)

Publication Number Publication Date
JP2020531511A JP2020531511A (ja) 2020-11-05
JP2020531511A5 true JP2020531511A5 (enExample) 2021-09-30

Family

ID=65439930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511176A Pending JP2020531511A (ja) 2017-08-24 2018-08-24 眼球用医薬組成物

Country Status (8)

Country Link
US (3) US11839616B2 (enExample)
EP (1) EP3672598A4 (enExample)
JP (1) JP2020531511A (enExample)
KR (1) KR20200044873A (enExample)
CN (1) CN111629730A (enExample)
AU (1) AU2018321926B2 (enExample)
CA (1) CA3073718A1 (enExample)
WO (1) WO2019040919A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
US11957413B2 (en) * 2019-08-06 2024-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education Solitary wave-based trans-lid tonometer
TWI845795B (zh) * 2019-12-05 2024-06-21 美商汎達製藥公司 眼用醫藥組合物
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
CN116507336B (zh) * 2020-09-10 2026-01-02 Vanda制药公司 治疗pde iv介导的疾病或病症的方法
AU2025224045A1 (en) * 2024-02-22 2026-08-06 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPS62126178A (ja) 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
AU5433594A (en) 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
IL137128A0 (en) 1998-01-30 2001-07-24 R Tech Ueno Ltd Ophthalmic compositions containing tetrahydroquinazoline derivatives
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
BR9815785A (pt) 1998-03-31 2000-12-05 Warner Lambert Co Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
PL369600A1 (en) 2001-09-21 2005-05-02 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2004031184A1 (en) 2002-10-01 2004-04-15 Johnson & Johnson Pharmaceutical Research & Development, Inc. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
WO2005009980A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
BRPI0507278A (pt) 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
US8080563B2 (en) 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
US8263607B2 (en) 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
WO2009091388A2 (en) 2007-12-21 2009-07-23 Progenics Pharmaceuticals, Inc. Triazines and related compounds having antiviral activity, compositions and methods thereof
ES2548583T3 (es) 2008-03-05 2015-10-19 Merck Patent Gmbh Derivados de quinoxalinona como estimuladores de la secreción de insulina, métodos para su obtención y su uso para el tratamiento de la diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
CA2895656A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US10354851B2 (en) 2015-09-11 2019-07-16 Iontof Technologies Gmbh Secondary ion mass spectrometer and secondary ion mass spectrometric method
US10035962B2 (en) * 2015-12-21 2018-07-31 Exxonmobil Research And Engineering Company Trim dewaxing of distillate fuel
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
ES2956820T3 (es) 2015-12-24 2023-12-28 Respivert Ltd Compuestos de indolinonas y su uso en el tratamiento de enfermedades fibróticas
RU2730855C2 (ru) 2015-12-24 2020-08-26 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
RU2742934C2 (ru) 2015-12-24 2021-02-11 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물

Similar Documents

Publication Publication Date Title
JP7863279B2 (ja) 眼科用組成物
Moiseev et al. Penetration enhancers in ocular drug delivery
JP7012075B2 (ja) 眼瞼炎の治療に使用するための医薬組成物
CN105307498B (zh) 用于治疗眼病的组合物、制剂和方法
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
NZ785712A (en) Neuroactive steroids, compositions, and uses thereof
RU2017129247A (ru) Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
JP2009530234A5 (enExample)
JP2011516477A5 (enExample)
TN2010000251A1 (fr) N-acetyl-dl-leucine medicament neuro et retino protecteur
JP2019529541A5 (enExample)
JP2017520527A5 (enExample)
JP2013534527A5 (enExample)
EA201300314A1 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
JP2009501726A (ja) 眼科学的活性剤の製剤とその投与の方法
Cegielska et al. Targeted drug delivery systems for the treatment of glaucoma: Most advanced systems review
WO2016208961A1 (ko) 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
JP6871400B2 (ja) 眼表面疾患の治療のための製剤および関連方法
US9320645B2 (en) Approach to administering ocular medication
JP2018500546A5 (enExample)
JP2008540528A5 (enExample)
EP4225279A1 (en) Drug containing dissolvable ocular inserts and method of using same
JP2018519299A (ja) 組成物および治療方法
JP2019502719A5 (enExample)
CN103720524A (zh) 一种制作灵长类动物干性年龄相关性黄斑变性疾病模型的方法